Iteos Home

SEC Filings

Home / Investors / SEC Filings

SEC Filings

iTeos Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients. We leverage our deep understanding of tumor immunology and immunosuppressive pathways to design novel product candidates with the potential to restore the immune response against cancer.

Our innovative pipeline includes two clinical-stage programs targeting novel, validated immuno-oncology pathways designed with optimized pharmacologic properties for improved clinical outcomes. The first antibody product candidate, EOS-448, is a high affinity, potent, anti-TIGIT antibody with a functional Fc domain, designed to enhance the anti-tumor response through a multifaceted immune modulatory mechanism, currently progressing in multiple indications in collaboration with GSK. The Company is also advancing inupadenant, a next-generation adenosine A2A receptor antagonist tailored to overcome cancer immunosuppression into proof-of concept trials in several indications following encouraging single-agent activity in Phase 1.

iTeos Therapeutics is headquartered in Watertown, MA with a research center in Gosselies, Belgium.

For investors

Discover more about iTeos Therapeutics, our science, and our high potential for investment.

SEC Filings

Filing date Form Description Filing Group View
SC 13G/A

An amendment to the SC 13G filing
Other
 View HTML
0001273087-24-000004.pdf
0001273087-24-000004.rtf
0001273087-24-000004.xls
8-K

Report of unscheduled material events or corporate event
Current Reports
 View HTML
0000950170-23-068807.pdf
0000950170-23-068807.rtf
0000950170-23-068807.xls
EX-101.PRE - XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
3

Initial filing by director officer or owner of more than ten percent
3,4,5
 View HTML
0000950170-23-068897.pdf
0000950170-23-068897.rtf
0000950170-23-068897.xls
4

Statement of changes in beneficial ownership of securities
3,4,5
 View HTML
0000950170-23-068899.pdf
0000950170-23-068899.rtf
0000950170-23-068899.xls
4

Statement of changes in beneficial ownership of securities
3,4,5
 View HTML
0000950170-23-068901.pdf
0000950170-23-068901.rtf
0000950170-23-068901.xls
4

Statement of changes in beneficial ownership of securities
3,4,5
 View HTML
0000950170-23-068900.pdf
0000950170-23-068900.rtf
0000950170-23-068900.xls
4

Statement of changes in beneficial ownership of securities
3,4,5
 View HTML
0000950170-23-068903.pdf
0000950170-23-068903.rtf
0000950170-23-068903.xls
4

Statement of changes in beneficial ownership of securities
3,4,5
 View HTML
0000950170-23-068902.pdf
0000950170-23-068902.rtf
0000950170-23-068902.xls
10-Q

Quarterly report which provides a continuing view of a company's financial position
Quarterly Filings
 View HTML
0000950170-23-059757.pdf
0000950170-23-059757.rtf
0000950170-23-059757.xls
EX-101.DEF - XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
SC 13G

A statement of beneficial ownership of common stock by certain persons
Other
 View HTML
0001273087-23-000143.pdf
0001273087-23-000143.rtf
0001273087-23-000143.xls
Displaying 51 - 60 of 331 results

Data provided by Kaleidoscope.

Cancer Cells graphics

At iTeos we are pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics.

Our differentiated development approach is driven by biologic rationale and clinical need utilizing our IO candidates in intra-portfolio combinations and with programs of external collaborators.

Driven by a culture of scientific innovation, collaboration and excellence, together we discover and deliver breakthrough immunotherapies to improve and extend the lives of people with cancer.